Biohaven embraces digital to keep migraine launch on track despite COVID-19

Biohaven only won FDA approval for its new migraine drug one month ago, but a lot has changed around the world since then. Amid the COVID-19 pandemic, the company is embracing digital communications to keep the rollout on track despite social distancing measures.

Leave a Reply

Your email address will not be published. Required fields are marked *